Genotypes rs9391981 CG (RIPK1), rs724165 GG (RIPK3), rs3212243 GG (RIPK3) and rs4073250 AA (MAPKAPK2) were found to be independent prognostic factors connected with a reduction in overall survival in patients with multiple myeloma, while genotype rs4073250 AA (MAPKAPK2) also led to reduction in progression-free survival. Here, MAPKAPK2 is linked to plasma cell myeloma.